UiPath Inc. (NYSE:PATH) Shares Bought by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in UiPath Inc. (NYSE:PATH) by 5.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 41,421 shares of the healthcare company’s stock after buying an additional 2,158 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in UiPath were worth $525,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Mark Sheptoff Financial Planning LLC acquired a new position in UiPath in the fourth quarter valued at approximately $25,000. ORG Partners LLC lifted its holdings in shares of UiPath by 875.6% in the 1st quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock worth $27,000 after purchasing an additional 1,112 shares during the last quarter. Lindbrook Capital LLC boosted its position in UiPath by 46.0% during the 1st quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock valued at $46,000 after purchasing an additional 639 shares during the period. GAMMA Investing LLC grew its stake in UiPath by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock worth $50,000 after buying an additional 632 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its position in UiPath by 122.5% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,556 shares of the healthcare company’s stock worth $58,000 after buying an additional 1,407 shares during the period. Institutional investors own 62.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on PATH. Scotiabank lowered their price target on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating for the company in a research report on Wednesday, May 29th. Barclays dropped their price target on shares of UiPath from $16.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Monday, August 19th. JPMorgan Chase & Co. reduced their price objective on UiPath from $28.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, May 30th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a research report on Thursday, May 30th. Finally, TD Cowen reiterated a “hold” rating and set a $17.00 price target (down previously from $28.00) on shares of UiPath in a research report on Thursday, May 30th. Sixteen research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $17.94.

UiPath Trading Down 2.2 %

NYSE:PATH opened at $12.60 on Wednesday. The company has a 50-day moving average of $12.21 and a 200-day moving average of $16.86. The firm has a market cap of $7.22 billion, a price-to-earnings ratio of -78.75 and a beta of 0.86. UiPath Inc. has a twelve month low of $10.37 and a twelve month high of $27.87.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.